Post Profile

Cabozantinib Shows Significant Activity in the First Line for Differentiated Thyroid Cancer

Results of a new phase II clinical trial indicate that cabozantinib offers an active therapy option for patients with differentiated thyroid cancer (DTC) that has progressed following surgery and treatment with radioactive iodine (RAI). Thirty-four of 35 patients in the trial experienced a reduction in tumor size following treatment with the targeted kinase inhibitor, and more than half experienced reductions in excess of 30 percent.
read more


Related Posts

Thyroid Cancer Radio Iodine Treatment; Who Is Receiving It And Why?

Health : Medical News Today

Radioactive iodine usage after thyroid surgery for different stages of thyroid cancer is up, but there are few guidelines outlining proper dosages and usage. So what is it and what do patients and health providers need to know? Firs...

Anti-Cancer Drug Linked to Tumor Shrinkage in Patients with Advanced Differentiated Thyroid Cancer

Health : Newswise Medical News

Researchers tested the effectiveness of lenvatinib in patients with advanced, progressive differentiated thyroid cancer (DTC) that does not respond to conventional radioiodine therapy. Data demonstrated a partial response in 45%-50%...

Radioactive Iodine Treatment Should Be Used in Some but Not All Cases of Papillary Thyroid Cancer

Health : Newswise Medical News

Radioactive iodine should only be used in the treatment of some patients with papillary thyroid cancer, according to data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Quebec City, Quebec, Canada.

New Radioactive Drug Shows Impressive Results In Early Hodgkin's Lymphoma

Health : Medical News Today

TWO THIRDS of Hodgkin's lymphoma patients treated with an experimental radioactive cancer therapy responded well to the treatment, reveal the results of a Cancer Research UK phase I trial published in Clinical Cancer Research. Resea...

Sorafenib Stops Tumor Growth And Provides The First Effective Treatment For Thyroid Cancer Patients Who Progress Following Standard Therapies

Health : Medical News Today

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which was presented by a researcher from the Abramson Can...


Copyright © 2016 Regator, LLC